Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA4 | P22748 | 3/20 | 0.67 |
| ▸ | CA7 | P43166 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GRK2 | P25098 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776720 | 1.00 | CA12 (0.67) | CA12CA1CA2CA4CA7 | |
| SCHEMBL3365962 | 1.00 | CA12 (0.67) | CA12CA1CA2CA4CA7 | |
| SCHEMBL20676025 | 0.93 | CA12 (0.74) | CA12CA1CA2CA4CA7 | |
| SCHEMBL20116495 | 0.86 | CA12 (0.66) | CA12CA1CA2CA4CA7 | |
| SCHEMBL892508 | 0.86 | CA12 (0.66) | CA12CA1CA2CA4CA7 | |
| SCHEMBL17967205 | 0.85 | RECQL (0.72) | CA12CA1CA2CA4CA7 | |
| SCHEMBL895795 | 0.85 | TSHR (0.67) | CA12CA1CA2CA4CA7 | |
| SCHEMBL20676027 | 0.85 | CA12 (0.65) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2766820 | 0.85 | RXFP1 (0.68) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2221436 | 0.85 | TSHR (0.71) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148362-B2 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | claimed |
| EP-1664323-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | claimed |
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | claimed |
| WO-2005026373-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | WO | claimed |
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-20070032542-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | IDING HANS | 2007-02-08 | — | — | US | disclosed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7148362-B2 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1664323-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005026373-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | MAOB, MAOA, CYP1B1 | CA12 4536/4885CA1 4459/4885CA2 4203/4885 |
| US-20070032542-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | MAOB, MAOA, CYP1B1 | CA12 4536/4885CA1 4459/4885CA2 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.